Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: It seems to me that
i can argue with all the points u have made. when u are a young company trying to establish itself and u dump the treasury to appease the debt financier u send the wrong message. the dividend play would only have worked if we had a huge treasury or we knew we were expecting immediate replacement capital. with regards to the acquisition, talk is cheap. might we not be in a better position as a company if the treasury was not off loaded to its "sharehholders" in pursuit of that acquisition? i am not arguing that we have not experienced price appreciation from the lows but i am stating that the BOD has had nothing to do with this and their few decisions have not benefited the sharehholder....yet they granted themselves options. i would like the BOD to address what we are doing with the office space we rented? or is this again a well thought out move by the "shoes" on the BOD? please point out your favorite BOD decision that has benefited the share price? teremoto
Share
New Message
Please login to post a reply